In short
A groundbreaking clinical trial is underway to assess the safety and efficacy of Trehalose Dihydrate (Ph.eur.), known as SLS-005, for treating adults with Spinocerebellar Ataxia Type 3 (SCA3). This double-blind, randomized, placebo-controlled study aims to evaluate the potential of this investigational drug in managing the symptoms of this rare neurological disorder. The trial, named STRIDES, offers hope for patients suffering from SCA3 and could potentially lead to new treatment options for this challenging condition.
At a glance
- Study Name
- STRIDES
- Drug Name
- SLS-005 (Trehalose Dihydrate)
- Condition
- Spinocerebellar Ataxia Type 3 (SCA3)
- Study Design
- Double-blind, randomized, placebo-controlled
- Treatment Duration
- 52 weeks
- Primary Endpoint
- Change in m-SARA total score at Week 52
- Key Secondary Endpoints
- Changes in CGI-S, PGI-S, FARS-ADL scores
- Administration
- Intravenous infusion
- Dosage
- 0.75 g/kg (higher dose arm)
- Age Range
- 18 to 75 years
What is Trehalose Dihydrate?
Trehalose Dihydrate, also known as SLS-005, is an investigational drug being studied for the treatment of Spinocerebellar Ataxia Type-3 (SCA3). It is a chemical compound that is being tested to see if it can help people with this rare neurological disorder. Trehalose is a type of sugar that occurs naturally in some organisms and has shown potential in protecting brain cells.
Understanding Spinocerebellar Ataxia Type-3 (SCA3)
Spinocerebellar Ataxia Type-3 (SCA3), also known as Machado-Joseph disease, is a rare genetic disorder that affects the nervous system. It causes progressive problems with movement, balance, and coordination. People with SCA3 may experience difficulties with walking, speaking, and performing daily activities as the disease progresses.
Clinical Trial: STRIDES Study
A clinical trial called STRIDES (A Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia) is currently underway to test the safety and effectiveness of Trehalose Dihydrate in treating adults with SCA3. This study is:
- Double-blind: Neither the participants nor the researchers know who is receiving the actual drug or a placebo.
- Randomized: Participants are randomly assigned to different treatment groups.
- Placebo-controlled: Some participants receive a placebo (a substance with no active ingredients) for comparison.
The main goal of this study is to determine if Trehalose Dihydrate can effectively treat SCA3 in adults and to assess its safety and tolerability.
How is Trehalose Dihydrate Administered?
In the STRIDES study, Trehalose Dihydrate (SLS-005) is given as an intravenous infusion. This means the medication is delivered directly into the bloodstream through a vein. The dosage being tested is 0.75 g/kg (grams per kilogram of body weight).
Who is Eligible for the Clinical Trial?
The study has specific criteria for who can participate. Some key eligibility requirements include:
- Adults aged 18 to 75 years
- Confirmed genetic diagnosis of SCA3
- Certain scores on movement and gait assessments
- Body Mass Index (BMI) between 18 and 35 kg/m²
There are also several conditions that would exclude someone from participating, such as other types of ataxia, certain medical conditions, or recent participation in other clinical trials.
How is the Effectiveness Measured?
The researchers use several methods to measure how well Trehalose Dihydrate works:
- m-SARA score: This is a scale that measures the severity of ataxia symptoms.
- Clinical Global Impression of Severity (CGI-S): This is the doctor's assessment of the severity of the patient's condition.
- Patient Global Impression of Severity (PGI-S): This is the patient's own assessment of their condition.
- Friedreich's Ataxia Rating Scale - Activities of Daily Living (FARS-ADL): This measures how well patients can perform everyday activities.
These assessments are done at various points throughout the 52-week study period to track changes over time.
Safety Considerations
As with any clinical trial, safety is a top priority. The researchers will closely monitor participants for any side effects or adverse reactions. Some safety measures include:
- Regular check-ups and laboratory tests
- Monitoring of liver and kidney function
- Cardiovascular assessments
- Screening for mental health concerns
It's important to note that Trehalose Dihydrate is still an investigational drug, which means it has not yet been approved for general use in treating SCA3. The STRIDES study aims to provide more information about its safety and effectiveness.